Home Endocrinology & Hormones Mineralocorticoid Receptor antagonist Finerenone For research use only.

Finerenone

Synonyms: FIN, BAY 94-8862

Finerenone (FIN, BAY 94-8862) is a highly selective and orally available nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.

Finerenone Chemical Structure

Finerenone Chemical Structure

CAS: 1050477-31-0

Purity & Quality Control

Batch: Purity: 99.97%
99.97

Finerenone Related Products

Choose Selective Mineralocorticoid Receptor Inhibitors

Biological Activity

Description Finerenone (FIN, BAY 94-8862) is a highly selective and orally available nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
Targets
MR [1]
(Cell-free assay)
18 nM
In vitro
In vitro

In vitro, Finerenone dose-dependently reduces aldosterone-induced smooth muscle cell (SMC) proliferation and prevents aldosteroneinduced endothelial cell (EC) apoptosis. Finerenone significantly reduces apoptosis of ECs and simultaneously attenuates SMC proliferation, resulting in accelerated endothelial healing and reduced neointima formation of the injured vessels.[2]
Cell Research Cell lines Human coronary artery smooth muscle cells (SMC), human umbilical vein endothelial cells (EC)
Concentrations 1 nM, 10 nM
Incubation Time 24 h
Method

Cells are incubated with aldosterone with or without finerenone for 24 hours after 24 hours of serum-starvation for the assessment of cell proliferation and apoptosis. Immediately prior to the addition of aldosterone, cells are preincubated with finerenone or vehicle for 30 minutes.
In Vivo
In vivo

Finerenone improves endothelial dysfunction through an enhancement in NO bioavailability and a decrease in superoxide anion levels due to an upregulation in SOD activity. This is associated with an increase in renal SOD activity and a reduction of albuminuria.[1]
Animal Research Animal Models 12-week-old MWF, aged-matched normoalbuminuric Wistar rats
Dosages 10 mg/kg
Administration Oral gavage
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06330974 Not yet recruiting
Asthma|Asthma in Children|Allergy|Rhinitis Allergic|Atopic Dermatitis|Allergen Immunotherapy
Tampere University|Professor Lauri Lehtimäki|Professor Mika Mäkelä|Professor Sanna Toppila-Salmi|Professor Ilkka Junttila
 October 2024 --
NCT06402760 Not yet recruiting
Psoriasis|Diabetes
Shanghai Yueyang Integrated Medicine Hospital|Shanghai Hongkou District Center for Disease Control And Prevention
 July 1 2024 Early Phase 1
NCT06359418 Not yet recruiting
Obesity|Pre-diabetes
Guang''anmen Hospital of China Academy of Chinese Medical Sciences|Hubei Hospital of Traditional Chinese Medicine|The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine|Dongfang Hospital Beijing University of Chinese Medicine|Guangdong Provincial Hospital of Traditional Chinese Medicine|Heilongjiang Academy of traditional Chinese Medicine
 April 10 2024 Not Applicable

Chemical Information & Solubility

Molecular Weight 378.42 Formula

C21H22N4O3
CAS No. 1050477-31-0 SDF --
Smiles CCOC1=NC=C(C)C2=C1C(C3=CC=C(C=C3OC)C#N)C(=C(C)N2)C(N)=O
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 76 mg/mL ( (200.83 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 10 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Finerenone | Finerenone supplier | purchase Finerenone | Finerenone cost | Finerenone manufacturer | order Finerenone | Finerenone distributor